| Followers | 200 |
| Posts | 25597 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Saturday, April 29, 2023 9:11:09 PM
A BP partner accelerates things but getting approvals and having real income will change expectations immensely. As to where the stock price might be, I won't speculate, but that it could be well over a dollar, is definitely a possibility without a BP partner. Moreover, any approval is likely going to accelerate negotiations with potential partners and increase their willingness to pay more up front without worry that the bear case is somehow going to blow up in their face. This is the unfortunate impact of the AF's and their accolytes, they drive away capital intentionally, capital from retail, from institutional investors and also from BP's that might worry when they see such immense efforts to embarrass a company that it could rub off on them or be redirected at them.
I would like to see those persons held accountable at the end of the day, in some way or process. Hard to know if that will ever be the case, but I think most investors in excellent companies like NWBO often think the same thoughts after there is a success. The problem is that much graft and difficult to prosecute, mostly impossible to prosecute, crime happens in the "respectable" areas of finance and investments. The bad guys are not the entrepreneurs in a case like NWBO, but those who fleece the markets because they can get away with it. It's broad, we're not the only ones, but our long development challenges for dendritic cells, problems pioneered and made popular for shorting by DNDN, have drawn a certain element that hates to give up even when they are flat wrong. They are arrogant, almost insane with ego, and they are a problem. But the company will, I believe, beat them, and it of course was better and often is better with biotechs to get in late in the process when much of that nonsense has already mostly been done and at the lowest prices possible. That's what some of those same traders are trying to do now, in my opinion, get in, after shorting this for many years, get in or cover, at the lowest price possible before news that I think everyone, including the bears, know is likely coming, eventually.
I would like to see those persons held accountable at the end of the day, in some way or process. Hard to know if that will ever be the case, but I think most investors in excellent companies like NWBO often think the same thoughts after there is a success. The problem is that much graft and difficult to prosecute, mostly impossible to prosecute, crime happens in the "respectable" areas of finance and investments. The bad guys are not the entrepreneurs in a case like NWBO, but those who fleece the markets because they can get away with it. It's broad, we're not the only ones, but our long development challenges for dendritic cells, problems pioneered and made popular for shorting by DNDN, have drawn a certain element that hates to give up even when they are flat wrong. They are arrogant, almost insane with ego, and they are a problem. But the company will, I believe, beat them, and it of course was better and often is better with biotechs to get in late in the process when much of that nonsense has already mostly been done and at the lowest prices possible. That's what some of those same traders are trying to do now, in my opinion, get in, after shorting this for many years, get in or cover, at the lowest price possible before news that I think everyone, including the bears, know is likely coming, eventually.
Bullish
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
